Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Tax Provisions (2016 - 2025)

Sonoma Pharmaceuticals has reported Tax Provisions over the past 8 years, most recently at -$130000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions fell 1544.44% year-over-year to -$130000.0; the TTM value through Dec 2025 reached -$80000.0, down 900.0%, while the annual FY2025 figure was $550000.0, 380.61% up from the prior year.
  • Tax Provisions for Q4 2025 was -$130000.0 at Sonoma Pharmaceuticals, up from -$197000.0 in the prior quarter.
  • Over five years, Tax Provisions peaked at $713000.0 in Q1 2021 and troughed at -$292000.0 in Q1 2024.
  • A 5-year average of $65722.2 and a median of $7000.0 in 2021 define the central range for Tax Provisions.
  • Biggest five-year swings in Tax Provisions: skyrocketed 1900.0% in 2022 and later plummeted 1544.44% in 2025.
  • Year by year, Tax Provisions stood at $5000.0 in 2021, then soared by 580.0% to $34000.0 in 2022, then plummeted by 267.65% to -$57000.0 in 2023, then skyrocketed by 115.79% to $9000.0 in 2024, then plummeted by 1544.44% to -$130000.0 in 2025.
  • Business Quant data shows Tax Provisions for SNOA at -$130000.0 in Q4 2025, -$197000.0 in Q3 2025, and -$1000.0 in Q2 2025.